Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 6252

1.

Immunostimulatory activity of low-molecular-weight hyaluronan on dendritic cells stimulated with Aggregatibacter actinomycetemcomitans or Porphyromonas gingivalis.

Monasterio G, Guevara J, Ibarra JP, Castillo F, Díaz-Zúñiga J, Alvarez C, Cafferata EA, Vernal R.

Clin Oral Investig. 2018 Sep 17. doi: 10.1007/s00784-018-2641-5. [Epub ahead of print]

PMID:
30225677
2.

Targeting IL-23 in Crohn's disease.

Sedda S, Bevivino G, Monteleone G.

Expert Rev Clin Immunol. 2018 Sep 18. doi: 10.1080/1744666X.2018.1524754. [Epub ahead of print]

PMID:
30223688
3.

Corrigendum to "Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials" [Int. Immunopharmacol. 62 (2018) 46-58].

Cui L, Chen R, Subedi S, Yu Q, Gong Y, Chen Z, Shi Y.

Int Immunopharmacol. 2018 Sep 13. pii: S1567-5769(18)30494-6. doi: 10.1016/j.intimp.2018.08.039. [Epub ahead of print] No abstract available.

PMID:
30220547
4.

IL-23 inhibitors for moderate-to-severe psoriasis.

Ibler E, Gordon KB.

Semin Cutan Med Surg. 2018 Sep;37(3):158-162. doi: 10.12788/j.sder.2018.047.

PMID:
30215632
5.

IL-17 inhibitors for psoriasis.

Paek SY, Frieder J, Kivelevitch D, Menter MA.

Semin Cutan Med Surg. 2018 Sep;37(3):148-157. doi: 10.12788/j.sder.2018.051.

PMID:
30215631
6.

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date.

Beck KM, Sanchez IM, Yang EJ, Liao W.

Psoriasis (Auckl). 2018 Aug 29;8:49-58. doi: 10.2147/PTT.S146640. eCollection 2018. Review.

7.

Expression of IL-23R and IL-17 and the pathology and prognosis of urinary bladder carcinoma.

Liu J, Wang L, Wang T, Wang J.

Oncol Lett. 2018 Oct;16(4):4325-4330. doi: 10.3892/ol.2018.9145. Epub 2018 Jul 13.

8.

The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor α in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis.

Pirowska M, Obtułowicz A, Lipko-Godlewska S, Goździalska A, Podolec K, Wojas-Pelc A.

Postepy Dermatol Alergol. 2018 Aug;35(4):360-366. doi: 10.5114/ada.2018.77665. Epub 2018 Aug 21.

9.

Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight.

Nguyen CT, Bloch Y, Składanowska K, Savvides SN, Adamopoulos IE.

Clin Immunol. 2018 Sep 6. pii: S1521-6616(18)30476-5. doi: 10.1016/j.clim.2018.09.002. [Epub ahead of print]

PMID:
30196070
10.

IL-23 promotes the development of castration-resistant prostate cancer.

Yan J, Cua DJ, Teng MW.

Immunol Cell Biol. 2018 Sep 8. doi: 10.1111/imcb.12195. [Epub ahead of print] No abstract available.

PMID:
30194885
11.

Influenza infection directly alters innate IL-23 and IL-12p70 and subsequent IL-17A and IFN-γ responses to pneumococcus in vitro in human monocytes.

Loughran ST, Power PA, Maguire PT, McQuaid SL, Buchanan PJ, Jonsdottir I, Newman RW, Harvey R, Johnson PA.

PLoS One. 2018 Sep 7;13(9):e0203521. doi: 10.1371/journal.pone.0203521. eCollection 2018.

12.

Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis.

Hawkes JE, Yan BY, Chan TC, Krueger JG.

J Immunol. 2018 Sep 15;201(6):1605-1613. doi: 10.4049/jimmunol.1800013. Review.

PMID:
30181299
13.

Oxidized Low-Density Lipoprotein-Deteriorated Psoriasis Is Associated with the Upregulation of Lox-1 Receptor and Il-23 Expression In Vivo and In Vitro.

Shih CM, Huang CY, Wang KH, Huang CY, Wei PL, Chang YJ, Hsieh CK, Liu KT, Lee AW.

Int J Mol Sci. 2018 Sep 3;19(9). pii: E2610. doi: 10.3390/ijms19092610.

14.

The lack of PI3Kγ favors M1 macrophage polarization and does not prevent kidney diseases progression.

Amano MT, Castoldi A, Andrade-Oliveira V, Latancia MT, Terra FF, Correa-Costa M, Breda CNS, Felizardo RJF, Pereira WO, da Silva MB, Miyagi MYS, Aguiar CF, Hiyane MI, Silva JS, Moura IC, Camara NOS.

Int Immunopharmacol. 2018 Aug 31;64:151-161. doi: 10.1016/j.intimp.2018.08.020. [Epub ahead of print]

PMID:
30176533
15.

Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab.

Wechter T, Cline A, Feldman SR.

Ther Clin Risk Manag. 2018 Aug 22;14:1489-1497. doi: 10.2147/TCRM.S177127. eCollection 2018. Review.

16.

Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.

Furue K, Ito T, Furue M.

Cytokine. 2018 Aug 29;111:182-188. doi: 10.1016/j.cyto.2018.08.025. [Epub ahead of print] Review.

PMID:
30172115
17.

Beyond the TNF-α Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology.

Pedersen SJ, Maksymowych WP.

Drugs. 2018 Aug 31. doi: 10.1007/s40265-018-0971-x. [Epub ahead of print]

PMID:
30171593
18.

Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases.

Kaufman BP, Alexis AF.

Curr Allergy Asthma Rep. 2018 Aug 31;18(10):55. doi: 10.1007/s11882-018-0804-8. Review.

PMID:
30171358
19.

Distinguishing rheumatoid arthritis from psoriatic arthritis.

Merola JF, Espinoza LR, Fleischmann R.

RMD Open. 2018 Aug 13;4(2):e000656. doi: 10.1136/rmdopen-2018-000656. eCollection 2018.

20.

The vitamin D3 analog, maxacalcitol, reduces psoriasiform skin inflammation by inducing regulatory T cells and downregulating IL-23 and IL-17 production.

Hau CS, Shimizu T, Tada Y, Kamata M, Takeoka S, Shibata S, Mitsui A, Asano Y, Sugaya M, Kadono T, Sato S, Watanabe S.

J Dermatol Sci. 2018 Aug 24. pii: S0923-1811(18)30309-8. doi: 10.1016/j.jdermsci.2018.08.007. [Epub ahead of print]

PMID:
30166055

Supplemental Content

Loading ...
Support Center